SpringerLink
Log in

Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Adenosine A2A receptor antagonist istradefylline has been approved this year for manufacturing and marketing in Japan. We, therefore, did this meta-analysis to systematically assess the efficacy and safety of istradefylline as augmentation to levodopa in patients with Parkinson’s disease (PD). We systematically review the relative randomized controlled trials (RCTs) up to March 2014, which compared istradefylline to placebo for the short course of treatment for PD in adults. The primary outcome was daily OFF time and secondary outcome was UPDRS Part III score (on state). Data were obtained from seven RCTs, including 2205 patients. Compared to placebo on primary and secondary outcome, istradefylline group both showed significant reductions (WMD −0.60, p = 0.0001; WMD −1.07, p = 0.002). Subgroup analysis suggested that istradefylline 20, 40, and 60 mg/day in both group showed significant reductions on the two outcomes. Based on these results, Istradefylline could be an efficacy and safety augmentation drug added on to levodopa or other existing anti-Parkinsonian therapies. Limited by the number of studies, future large-scale studies are needed to verify these results, assess the long-term effect of istradefylline and the effect of istradefylline as monotherapy, and find the most effective dose of istradefylline.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fahn, S. (2003). Description of Parkinson’s disease as a clinical syndrome. Annals of the New York Academy of Sciences, 991, 1–14.

    Article  CAS  PubMed  Google Scholar 

  2. Barzilai, A., & Melamed, E. (2003). Molecular mechanisms of selective dopaminergic neuronal death in Parkinson’s disease. Trends in Molecular Medicine, 9(3), 126–132.

    Article  CAS  PubMed  Google Scholar 

  3. Dauer, W., & Przedborski, S. (2003). Parkinson’s disease: mechanisms and models. Neuron, 39(6), 889–909.

    Article  CAS  PubMed  Google Scholar 

  4. Dorsey, E. R., et al. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68(5), 384–386.

    Article  CAS  PubMed  Google Scholar 

  5. Bonuccelli, U. (2003). Comparing dopamine agonists in Parkinson’s disease. Current Opinion in Neurology, 16(Suppl 1), S13–S19.

    Article  CAS  PubMed  Google Scholar 

  6. Jenner, P. (2003). Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson’s disease. Current Opinion in Neurology, 16(Suppl 1), S3–S7.

    Article  CAS  PubMed  Google Scholar 

  7. Cieslak, M., Komoszynski, M., & Wojtczak, A. (2008). Adenosine A(2A) receptors in Parkinson’s disease treatment. Purinergic Signal, 4(4), 305–312.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Berlim, M. T., Van den Eynde, F., & Daskalakis, Z. J. (2013). A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychological Medicine, 43(11), 2245–2254.

    Article  CAS  PubMed  Google Scholar 

  9. Chen, J., et al. (2013). Left versus right repetitive transcranial magnetic stimulation in treating major depression: A meta-analysis of randomised controlled trials. Psychiatry Research, 210(3), 1260–1264.

    Article  PubMed  Google Scholar 

  10. Shiozaki, S., et al. (1999). Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl), 147(1), 90–95.

    Article  CAS  Google Scholar 

  11. Wenning, G. K., et al. (2013). The natural history of multiple system atrophy: A prospective European cohort study. Lancet Neurology, 12(3), 264–274.

    Article  PubMed Central  Google Scholar 

  12. Hauser, R. A., et al. (2008). Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Movement Disorders, 23(15), 2177–2185.

    Article  PubMed  Google Scholar 

  13. LeWitt, P. A., et al. (2008). Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Annals of Neurology, 63(3), 295–302.

    Article  CAS  PubMed  Google Scholar 

  14. Stacy, M., et al. (2008). A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology, 70(23), 2233–2240.

    Article  CAS  PubMed  Google Scholar 

  15. Dungo, R., & Deeks, E. D. (2013). Istradefylline: First global approval. Drugs, 73(8), 875–882.

    Article  CAS  PubMed  Google Scholar 

  16. Hughes, A. J., et al. (1992). What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology, 42(6), 1142–1146.

    Article  CAS  PubMed  Google Scholar 

  17. Sacks, H. S., et al. (1987). Meta-analyses of randomized controlled trials. New England Journal of Medicine, 316(8), 450–455.

    Article  CAS  PubMed  Google Scholar 

  18. Riley, R. D., Higgins, J. P., & Deeks, J. J. (2011). Interpretation of random effects meta-analyses. BMJ, 342, d549.

    Article  PubMed  Google Scholar 

  19. Higgins, J. P., et al. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Pourcher, E., et al. (2012). Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism and Related Disorders, 18(2), 178–184.

    Article  PubMed  Google Scholar 

  21. Mizuno, Y., Kondo, T., & G. Japanese Istradefylline Study. (2013). Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Movement Disorders, 28(8), 1138–1141.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Mizuno, Y., et al. (2010). Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: A randomized, controlled study. Movement Disorders, 25(10), 1437–1443.

    Article  PubMed  Google Scholar 

  23. Hauser, R. A., & Holford, N. H. (2002). Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson’s disease. Movement Disorders, 17(5), 961–968.

    Article  PubMed  Google Scholar 

  24. Kanda, T., et al. (2000). Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Experimental Neurology, 162(2), 321–327.

    Article  CAS  PubMed  Google Scholar 

  25. Grondin, R., et al. (1999). Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology, 52(8), 1673–1677.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, General Hospital of Shenyang Military Area Command, No. 83, Wenhua Road, Shenhe District, Shenyang, 110840, China

    Yingqun Tao & Guobiao Liang

Authors
  1. Yingqun Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guobiao Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yingqun Tao.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tao, Y., Liang, G. Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials. Cell Biochem Biophys 71, 57–62 (2015). https://doi.org/10.1007/s12013-014-0162-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0162-7

Keywords

Search

Navigation